M. Kruszynski

发表

[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

M. Manning, W. Sawyer, J. Seto, 1980, Journal of medicinal chemistry.

Pharmacodynamic enhancement of the anti-platelet antibody Fab abciximab by site-specific pegylation

R. Jordan, G. Heavner, S. Tam, 2004, Platelets.

Synthetic, site‐specific biotinylated analogs of human MCP‐1

J. F. Nemeth, Jinquan Luo, G. Heavner, 2006, Journal of peptide science : an official publication of the European Peptide Society.

Proteolytically Inactivated IgGs Reconstitute the Effector Functions of Human Anti-IgG1 Hinge Autoantibodies

D. Petrone, R. Jordan, S. Tam, 2008 .

Distribution of distances in thiopeptides by fluorescence energy transfer and frequency-domain fluorometry.

H. Szmacinski, M. Johnson, I. Gryczynski, 1988, Biophysical Chemistry.

Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

M. Manning, A. Olma, W. Sawyer, 1989, Journal of medicinal chemistry.

Design of potent and selective antagonists of the vasopressor responses to arginine-vasopressin.

M. Manning, W. Sawyer, J. Seto, 1982, Journal of medicinal chemistry.

Two novel thioamide analogues of TRH with selective activity on CNS.

G. Kupryszewski, V. S̆trbák, M. Kruszynski, 1991, General physiology and biophysics.

C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.

M. Manning, A. Misicka, A. Olma, 1987, Journal of medicinal chemistry.

No requirement of cyclic conformation of antagonists in binding to vasopressin receptors

M. Manning, W. H. Sawyer, A. Olma, 1987, Nature.

Potent V2 vasopressin antagonists with structural changes at their C-terminals

S. Stoev, M. Manning, A. Misicka, 1988, Peptides.

Invertebrate neuropeptides resembling vasotocin and some analogues: Synthesis and pharmacological properties

M. Manning, W. H. Sawyer, M. Kruszynski, 1990, Experientia.

Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position

M. Manning, A. Misicka, W. H. Sawyer, 1991, Experientia.

Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.

M. Manning, A. Olma, W. Sawyer, 2009, International journal of peptide and protein research.

Synthesis and biological characterization of human monocyte chemoattractant protein 1 (MCP‐1) and its analogs

Raymond Sweet, J. F. Nemeth, G. Heavner, 2006, Journal of peptide science : an official publication of the European Peptide Society.

Peptides from multiple regions of the lectin domain of P-selectin inhibiting neutrophil adhesion.

G. Heavner, D. Riexinger, M. Mervic, 2009, International journal of peptide and protein research.

Binding ability of thiocarbonyl-containing dipeptides. Potentiometric and spectroscopic studies of copper(II) and nickel(II) coordination

H. Kozłowski, I. Sóvágó, K. Várnagy, 1988 .

Synthesis by native chemical ligation and crystal structure of human CCL2

G. Gilliland, J. F. Nemeth, A. Teplyakov, 2010, Biopolymers.

The dimerization of glucagon‐like peptide‐2 MIMETIBODY™ is linked to leucine‐17 in the glucagon‐like peptide‐2 region

Haiyan Jiang, T. Nesspor, S. Sague, 2012, Journal of molecular recognition : JMR.

Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.

L. Gutshall, C. Palomo, J. Melero, 2007, The Journal of general virology.

Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.

S. Stoev, M. Manning, A. Misicka, 1990, Journal of medicinal chemistry.

Identification of TNF-alpha binding peptides from a D-amino acid hexapeptide library that specifically inhibit TNF-alpha binding to recombinant p55 receptor.

D. Shealy, G. Heavner, A. Leone, 1999, Cytokine.

Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs1

M. H. Ryan, D. Petrone, R. Jordan, 2008, The Journal of Immunology.

Human Anti-IgG 1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs 1

D. Petrone, R. Jordan, S. Tam, 2008 .

Chemical synthesis of the N-terminal cysteine-rich domain of human OX40.

J. F. Nemeth, Jinquan Luo, R. Sweet, 2009, Advances in Experimental Medicine and Biology.

Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants

R. Sweet, P. Tsui, N. Stowell, 2006 .

TRH analogue with C-terminal thioamide group. Synthesis, receptor binding, TSH-releasing activity and α-MSH-releasing activity

H. Vaudry, U. Ragnarsson, G. Kupryszewski, 1985, Experientia.

A synthetic peptide approach for elucidating the points of natural auto-antibody reactivity to proteolytic fragments of human IgG.

R. Jordan, G. Heavner, B. Whitaker, 2009, Advances in experimental medicine and biology.